Form 8-K - Current report:
SEC Accession No. 0001564590-21-049879
Filing Date
2021-10-04
Accepted
2021-10-04 07:01:38
Documents
12
Period of Report
2021-09-30
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K kalv-8k_20210930.htm   iXBRL 8-K 59606
  Complete submission text file 0001564590-21-049879.txt   189225

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA kalv-20210930.xsd EX-101.SCH 5685
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE kalv-20210930_lab.xml EX-101.LAB 19339
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kalv-20210930_pre.xml EX-101.PRE 11490
5 EXTRACTED XBRL INSTANCE DOCUMENT kalv-8k_20210930_htm.xml XML 3560
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

IRS No.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-36830 | Film No.: 211300981
SIC: 2834 Pharmaceutical Preparations